Gossamer Bio Narrows Q2 Loss Amidst Zero Revenue

Ticker: GOSS · Form: 10-Q · Filed: 2025-08-05T00:00:00.000Z

Sentiment: bearish

Topics: Biotech, Clinical Stage, Net Loss, No Revenue, Accumulated Deficit, SEC Filing, 10-Q Analysis

Related Tickers: GOSS

TL;DR

**GOSS is burning cash with no revenue, making it a high-risk bet on future pipeline success.**

AI Summary

Gossamer Bio, Inc. reported no revenue from contracts with collaborators for the three and six months ended June 30, 2025, consistent with the prior year's periods. The company's net loss for the three months ended June 30, 2025, was $35.4 million, a slight improvement from the $38.1 million net loss in the same period of 2024. For the six months ended June 30, 2025, the net loss was $70.1 million, compared to $75.2 million for the six months ended June 30, 2024. Total operating expenses for the three months ended June 30, 2025, were $35.4 million, down from $38.1 million in the prior year. The company's accumulated deficit increased to $1.2 billion as of June 30, 2025, from $1.1 billion as of December 31, 2024, reflecting ongoing R&D investments. Cash and cash equivalents were not explicitly detailed in the provided excerpt, but the consistent net losses indicate continued cash burn. The strategic outlook remains focused on pipeline development, with no significant new business changes reported in this period.

Why It Matters

Gossamer Bio's continued lack of revenue and persistent net losses, despite a slight improvement in Q2 2025, highlight the inherent risks of a clinical-stage biotech. Investors face significant dilution risk as the company will likely need to raise additional capital to fund its drug development pipeline, which could impact existing shareholders. Employees' job security is tied to successful clinical trials and future funding, while customers (future patients) depend on the company's ability to bring novel therapies to market. In a competitive biotech landscape, Gossamer's ability to advance its pipeline without a commercial product puts it at a disadvantage against more established pharmaceutical companies.

Risk Assessment

Risk Level: high — The company reported no revenue for the three and six months ended June 30, 2025, and an accumulated deficit of $1.2 billion as of June 30, 2025. This indicates a complete reliance on external funding and a significant cash burn, posing a high risk to investors due to potential future dilution and going concern issues.

Analyst Insight

Investors should approach GOSS with extreme caution, recognizing it as a speculative investment. Monitor upcoming clinical trial results closely and assess the company's cash runway, as further capital raises are highly probable and could dilute current holdings.

Financial Highlights

debt To Equity: N/A
revenue: $0
operating Margin: N/A
total Assets: N/A
total Debt: N/A
net Income: -$35.4M
eps: N/A
gross Margin: N/A
cash Position: N/A
revenue Growth: 0.0%

Revenue Breakdown

Segment	Revenue	Growth
Revenue from Contracts with Collaborators	$0	0.0%

Key Numbers

$0 — Revenue from contracts with collaborators (for Q2 2025 and H1 2025, indicating no commercial products)
$35.4M — Net Loss (Q2 2025) (Improved from $38.1M in Q2 2024, but still a significant loss)
$70.1M — Net Loss (H1 2025) (Improved from $75.2M in H1 2024, reflecting ongoing operational costs)
$1.2B — Accumulated Deficit (As of June 30, 2025, demonstrating substantial historical losses)

Key Players & Entities

Gossamer Bio, Inc. (company) — filer of the 10-Q
$35.4 million (dollar_amount) — net loss for Q2 2025
$38.1 million (dollar_amount) — net loss for Q2 2024
$70.1 million (dollar_amount) — net loss for H1 2025
$75.2 million (dollar_amount) — net loss for H1 2024
$1.2 billion (dollar_amount) — accumulated deficit as of June 30, 2025
$1.1 billion (dollar_amount) — accumulated deficit as of December 31, 2024
SEC (regulator) — recipient of the 10-Q filing
Bloomberg (company) — publisher of the analysis

FAQ

What was Gossamer Bio's revenue for the second quarter of 2025?

Gossamer Bio, Inc. reported no revenue from contracts with collaborators for the three months ended June 30, 2025, consistent with the prior year's period.

How did Gossamer Bio's net loss change in Q2 2025 compared to Q2 2024?

Gossamer Bio's net loss for the three months ended June 30, 2025, was $35.4 million, an improvement from the $38.1 million net loss reported in the same period of 2024.

What is Gossamer Bio's accumulated deficit as of June 30, 2025?

As of June 30, 2025, Gossamer Bio's accumulated deficit increased to $1.2 billion, up from $1.1 billion as of December 31, 2024.

What are the key financial risks for Gossamer Bio investors?

Key financial risks for Gossamer Bio investors include the company's lack of revenue, persistent net losses, and a significant accumulated deficit, indicating a high reliance on future capital raises and potential shareholder dilution.

Why does Gossamer Bio have no revenue from contracts with collaborators?

Gossamer Bio is a clinical-stage biotechnology company, meaning its primary focus is on research and development of drug candidates rather than commercial sales, hence the absence of product revenue.

What was the net loss for Gossamer Bio for the first six months of 2025?

For the six months ended June 30, 2025, Gossamer Bio reported a net loss of $70.1 million, an improvement from the $75.2 million net loss in the comparable period of 2024.

How does Gossamer Bio fund its operations without revenue?

Gossamer Bio funds its operations primarily through equity offerings, debt financing, and potentially upfront payments from collaboration agreements, as it does not generate revenue from product sales.

What is the significance of Gossamer Bio's accumulated deficit?

The accumulated deficit of $1.2 billion signifies the total historical losses incurred by Gossamer Bio since its inception, reflecting substantial investments in research and development without corresponding commercial returns.

What is Gossamer Bio's business strategy given its financial situation?

Gossamer Bio's business strategy is focused on advancing its pipeline of drug candidates through clinical trials, aiming for eventual regulatory approval and commercialization, which would then generate revenue.

What should investors consider regarding Gossamer Bio's future funding needs?

Investors should anticipate that Gossamer Bio will require additional capital raises in the future to sustain its operations and advance its pipeline, which could lead to further dilution of existing shareholder value.

Risk Factors

Sustained Net Losses and Accumulated Deficit [high — financial]: The company reported net losses of $35.4 million for Q2 2025 and $70.1 million for H1 2025. The accumulated deficit has grown to $1.2 billion as of June 30, 2025, indicating a significant historical burn rate and reliance on external funding.
Dependence on Pipeline Development [high — operational]: Gossamer Bio's strategy is heavily focused on pipeline development, with no revenue from commercial products reported. This makes the company highly dependent on the successful advancement and eventual commercialization of its drug candidates.
Continued Cash Burn [high — financial]: The consistent net losses and lack of revenue from collaborations suggest ongoing significant cash burn. While specific cash and cash equivalents are not detailed in the excerpt, this trend necessitates continuous access to capital to fund operations and R&D.
Drug Development and Regulatory Approval [high — regulatory]: As a biotechnology company, Gossamer Bio faces inherent risks associated with the lengthy and expensive process of drug development, including clinical trials and regulatory approvals from bodies like the FDA. Failure at any stage can lead to significant financial setbacks.

Industry Context

Gossamer Bio operates in the highly competitive biotechnology sector, characterized by significant R&D investment and long development cycles. The industry is driven by innovation in drug discovery and the pursuit of regulatory approvals for novel therapies. Companies like Gossamer Bio often rely on venture capital or public markets to fund their operations until a product reaches commercialization.

Regulatory Implications

The company's operations are subject to stringent regulations by health authorities such as the FDA. Successful navigation of clinical trials and the approval process is critical. Any delays or failures in regulatory submissions can have a material adverse impact on the company's financial health and stock valuation.

What Investors Should Do

[object Object]
[object Object]
[object Object]

Key Dates

2025-06-30: End of Q2 2025 reporting period — Marks the period for which financial results, including net loss and accumulated deficit, are reported.
2025-08-05: 10-Q Filing Date — Indicates the official release of the quarterly financial report to the public and SEC.

Glossary

Accumulated Deficit: The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total losses that have not been offset by profits. (Shows the company's historical unprofitability and the extent of its cumulative losses, which stood at $1.2 billion as of June 30, 2025.)
Revenue from Contracts with Collaborators: Income generated by a company from agreements with other entities for the development, manufacturing, or commercialization of products or technologies. (Gossamer Bio reported $0 in this category for the periods ending June 30, 2025, indicating no current commercial partnerships generating revenue.)
Net Loss: The total expenses of a company exceed its total revenues over a specific period. (Gossamer Bio reported net losses of $35.4 million for Q2 2025 and $70.1 million for H1 2025, highlighting ongoing operational costs and R&D investments.)

Year-Over-Year Comparison

Compared to the prior year's periods, Gossamer Bio has maintained zero revenue from contracts with collaborators for both the three and six months ended June 30, 2025. While net losses have slightly improved ($35.4M vs $38.1M for Q2, and $70.1M vs $75.2M for H1), the accumulated deficit has increased to $1.2 billion from $1.1 billion at the end of 2024, underscoring continued operational expenses and R&D investments without corresponding revenue generation.

From the Filing

0001728117-25-000068.txt : 20250805 0001728117-25-000068.hdr.sgml : 20250805 20250805160204 ACCESSION NUMBER: 0001728117-25-000068 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 73 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250805 DATE AS OF CHANGE: 20250805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gossamer Bio, Inc. CENTRAL INDEX KEY: 0001728117 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 475461709 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38796 FILM NUMBER: 251184759 BUSINESS ADDRESS: STREET 1: 3115 MERRYFIELD ROW STREET 2: SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 684-1300 MAIL ADDRESS: STREET 1: 3115 MERRYFIELD ROW STREET 2: SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92121 10-Q 1 goss-20250630.htm 10-Q goss-20250630 FALSE 2025 Q2 0001728117 12-31 0.0616095 xbrli:shares iso4217:USD iso4217:USD xbrli:shares goss:segment xbrli:pure goss:security goss:tranche goss:tradingDay goss:vote goss:day utr:sqft goss:month goss:performanceObligation goss:license 0001728117 2025-01-01 2025-06-30 0001728117 2025-07-31 0001728117 2025-06-30 0001728117 2024-12-31 0001728117 us-gaap:LicenseAndServiceMember 2025-04-01 2025-06-30 0001728117 us-gaap:LicenseAndServiceMember 2024-04-01 2024-06-30 0001728117 us-gaap:LicenseAndServiceMember 2025-01-01 2025-06-30 0001728117 us-gaap:LicenseAndServiceMember 2024-01-01 2024-06-30 0001728117 goss:RevenueFromContractsWithCollaboratorsMember 2025-04-01 2025-06-30 0001728117 goss:RevenueFromContractsWithCollaboratorsMember 2024-04-01 2024-06-30 0001728117 goss:RevenueFromContractsWithCollaboratorsMember 2025-01-01 2025-06-30 0001728117 goss:RevenueFromContractsWithCollaboratorsMember 2024-01-01 2024-06-30 0001728117 2025-04-01 2025-06-30 0001728117 2024-04-01 2024-06-30 0001728117 2024-01-01 2024-06-30 0001728117 us-gaap:CommonStockMember 2024-12-31 0001728117 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001728117 us-gaap:RetainedEarningsMember 2024-12-31 0001728117 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001728117 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001728117 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001728117 2025-01-01 2025-03-31 0001728117 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001728117 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001728117 us-gaap:CommonStockMember 2025-03-31 0001728117 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001728117 us-gaap:RetainedEarningsMember 2025-03-31 0001728117 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001728117 2025-03-31 0001728117 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001728117 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001728117 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001728117 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001728117 us-gaap:CommonStockMember 2025-06-30 0001728117 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001728117 us-gaap:RetainedEarningsMember 2025-06-30 0001728117 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001728117 us-gaap:CommonStockMember 2023-12-31 0001728117 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001728117 us-gaap:RetainedEarningsMember 2023-12-31 0001728117 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001728117 2023-12-31 0001728117 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001728117 2024-01-01 2024-03-31 0001728117 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001728117 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001728117 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001728117 us-gaap:CommonStockMember 2024-03-31 0001728117 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001728117 us-gaap:RetainedEarningsMember 2024-03-31 0001728117 us-gaa